Trial Profile

An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edralbrutinib (Primary)
Indications Neuromyelitis optica
Focus Proof of concept; Therapeutic Use
Sponsors Reistone Biopharma

Most Recent Events

21 Mar 2023 Status changed from active, no longer recruiting to completed.
19 Oct 2021 Status changed from recruiting to active, no longer recruiting.
06 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com